MRGX receptor antagonists

A method for treating a disease or disorder that is associated with the MrgX2 receptor, comprising administering to a subject in need thereof a therapeutically effective amount of an MrgX2 antagonist according to general formulas (II), (III), and (VII):

• wherein
• R1 means C1-3 alkyl, linear or branched, saturated or unsaturated, either unsubstituted or monosubstituted with —OH;
• R2 means CH(CH3)2, —CH2CH(CH3)2, —C(CH3)3, -cyclopropyl, -para-methoxyphenyl, -2-thienyl, —CH2C(═O)OH, —C(═O)OCH3, —CH2C(═O)OCH3, —CH2C(═O)OCH2CH3, —C(CH3)2(OH), —CH2OCH3, —SCH3, or —NH2;
• or
• R1 and R2 together with the atoms to which they are attached form a six membered saturated unsubstituted alicyclic ring;
• R3, and R4 means —H;
• —C1-6-alkyl;
• —C1-6-cycloalkyl;
• -phenyl;
• —C1-6-alkyl-phenyl;
• -heteroaryl selected from the group consisting of thienyl, furanyl and pyrrolyl;
• —C(═O)OH;
• —C(═O)O—C1-6-alkyl;
• —CN;
• —OH;
• —O—C1-6-alkyl, —NH2, —S—C1-6-alkyl, —F, —Cl, —Br, or —I;
• R5, R6, R7 and R8 independently of one another mean, —C1-6-alkyl, —CN, —OH, —O—C1-6-alkyl, —F, —Cl, —Br, or —I;
• or
• R6 and R7 together with the carbon atoms to which they are attached form an unsubstituted phenyl ring;
• wherein in each case the “C1-6-alkyl” may be linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with a substituent selected from —CN, —C(═O)OH, —C(═O)O—C1-6-alkyl, —OH, —O—C1-6-alkyl, —NH2, —NH—C1-6-alkyl, —N(C1-6-alkyl) 2, —N3, —F, —Cl, —Br, or —I;
• wherein in each case the “C1-6-cycloalkyl” may be linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with a substituent selected from —CN, —C(═O)OH, —C(═O)O—C1-6-alkyl, —OH, —O—C1-6-alkyl, —NH2, —NH—C1-6-alkyl, —N(C1-6-alkyl) 2, —N3, —F, —Cl, —Br, or —I;
• wherein in each case the “phenyl” may be unsubstituted, mono- or disubstituted with a substituent independently selected from —CN, —C(═O)OH, —C(═O)O—C1-6-alkyl, —OH, —O—C1-6-alkyl, —NH2, —NH—C1-6-alkyl, —N(C1-6-alkyl) 2, —N3, —F, —Cl, —Br, or —I;
• wherein in each case the “heteroaryl” may be linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with a substituent selected from —CN, —C(═O)OH, —C(═O)O—C1-6-alkyl, —OH, —O—C1-6-alkyl, —NH2, —NH—C1-6-alkyl, —N(C1-6-alkyl) 2, —N3, —F, —Cl, —Br, or —I;
• or
• a physiologically acceptable salt thereof.